Efficacy of meningococcal serogroup C conjugate va... Catalogue en ligne

Titre :	Efficacy of meningococcal serogroup C conjugate vaccine in teenagers and toddlers in England. (2001)
Auteurs :	Mary-E RAMSAY ; Nick ANDREWS ; Edward-B KACZMARSKI ; Elizabeth MILLER ; Immunisation Division. Phls Communicable Disease Surveillance Centre. London. GBR
Type de document :	Article
Dans :	Lancet (The) (vol. 357, n° 9251, 2001)
Pagination :	195-196
Langues:	Anglais
Mots-clés :	Bactériose ; Infection ; Prévention santé ; Angleterre ; Grande Bretagne ; Royaume Uni ; Europe ; Enfant ; Homme ; Adolescent
Résumé :	[BDSP. Notice produite par INIST FxUR0x7Z. Diffusion soumise à autorisation]. The UK was the first country to use meningococcal serogroup C conjugate (MCC) vaccines, which were licensed on the basis of immunogenicity and safety data but without a formal efficacy study. Increased surveillance during the first 9 months since Introduction has shown that short-term efficacy of the MCC vaccine In England was 97% (95% CI 77-99) for teenagers and 92% (65-98) for toddlers. These early results confirm the superiority of MCC over plain C polysaccharide vaccines, which are Ineffective in young children.

PORTAIL DOCUMENTAIRE